FEB 3, 2021: SOUVIE BIODELIVERY AWARDED BY NSF SBIR GRANT

Souvie Biodelivery was awarded by NSF a phase 1 SBIR grant. Our drug delivery platform transports its therapeutic payload to and into target cells, while having almost no effect on healthy cells. The outcome is improved effectiveness of drugs, better patient compliance, and virtually elimination of adverse side effects that otherwise disrupt patient's lives.